Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
CHAT	1103	STANOLONE	CHEMBL27769		NCI	6873629
CHAT	1103	ALCOHOL	CHEMBL545		NCI	3996882, 8247273
CHAT	1103	SODIUM CHLORIDE	CHEMBL1200574		NCI	566752
CHAT	1103	LIOTHYRONINE SODIUM	CHEMBL1201119		NCI	4017971
CHAT	1103	DEXAMETHASONE	CHEMBL384467		NCI	8905330
CHAT	1103	TESTOSTERONE	CHEMBL386630		NCI	7378793
CHAT	1103	PILOCARPINE	CHEMBL550		NCI	842358

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
CHAT	rs3810950	A	olanzapine	"dosage","efficacy"	no	This association was described as a trend. Uncorrected p = 0.061; corrected p = 0.18.	Allele A is associated with increased response to olanzapine in people with Schizophrenia as compared to allele G.	17503482	982015543
CHAT	rs1880676	A	olanzapine	"dosage","efficacy"	yes	This association was nominally significant (p= 0.04) in the Spanish cohort but not in the Basque cohort, but if corrected for the 3 SNPs tested, p = 0.12.	Allele A is associated with increased response to olanzapine in people with Schizophrenia as compared to allele G.	17503482	982015513
CHAT	rs2177369	AA	donepezil	efficacy	no	Response to donepezil was assessed by the mini mental state examination (MMSE) at baseline and at 1, 3, 9 and 15 months after beginning therapy.	Genotype AA is not associated with response to donepezil in people with Alzheimer Disease as compared to genotypes AG + GG.	18780301	1185235112
CHAT	rs7094421	A	donepezil	efficacy	yes	Presented as trend test of AA, AG, and GG in responder vs non responder. Donepezil 84 patients, galantamine 52 patients, rivastigmine 22 patients. No significant differences in genotype by drug type. Patients assessed after 1 week and 4 weeks of therapy to adjust dosage and evaluate adverse events. Response rate assessed at 26 weeks of treatment.	Allele A is not associated with response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele G.	25730470	1447679260
CHAT	rs7076926	C	donepezil	efficacy	yes	Presented as trend test of CC, CT, and TT in responder vs non responder. Donepezil 84 patients, galantamine 52 patients, rivastigmine 22 patients. No significant differences in genotype by drug type. Patients assessed after 1 week and 4 weeks of therapy to adjust dosage and evaluate adverse events. Response rate assessed at 26 weeks of treatment.	Allele C is not associated with response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele T.	25730470	1447679252
CHAT	rs10776586	C	donepezil	efficacy	yes	Presented as trend test of CC, CT, and TT in responder vs non responder. Donepezil 84 patients, galantamine 52 patients, rivastigmine 22 patients. No significant differences in genotype by drug type. Patients assessed after 1 week and 4 weeks of therapy to adjust dosage and evaluate adverse events. Response rate assessed at 26 weeks of treatment.	Allele C is not associated with response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele T.	25730470	1447679234
CHAT	rs7094248	G	donepezil	efficacy	yes	Presented as trend test of CC, CG, and GG in responder vs non responder. Donepezil 84 patients, galantamine 52 patients, rivastigmine 22 patients. No significant differences in genotype by drug type. Patients assessed after 1 week and 4 weeks of therapy to adjust dosage and evaluate adverse events. Response rate assessed at 26 weeks of treatment.	Allele G is not associated with response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele C.	25730470	1447679211
CHAT	rs11101193	G	donepezil	efficacy	yes	Presented as trend test of GG, GT, and TT in responder vs non responder. Donepezil 84 patients, galantamine 52 patients, rivastigmine 22 patients. No significant differences in genotype by drug type. Patients assessed after 1 week and 4 weeks of therapy to adjust dosage and evaluate adverse events. Response rate assessed at 26 weeks of treatment.	Allele G is not associated with response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele T.	25730470	1447679217
CHAT	rs12264845	C	donepezil	efficacy	yes	Presented as trend test of AA, AC, and CC in responder vs non responder. Donepezil 84 patients, galantamine 52 patients, rivastigmine 22 patients. No significant differences in genotype by drug type. Patients assessed after 1 week and 4 weeks of therapy to adjust dosage and evaluate adverse events. Response rate assessed at 26 weeks of treatment.	Allele C is not associated with response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele A.	25730470	1447679245
CHAT	rs11101192	G	donepezil	efficacy	yes	Presented as trend test of AA,AG, and GG in responder vs non responder. Donepezil 84 patients, galantamine 52 patients, rivastigmine 22 patients. No significant differences in genotype by drug type. Patients assessed after 1 week and 4 weeks of therapy to adjust dosage and evaluate adverse events. Response rate assessed at 26 weeks of treatment.	Allele G is not associated with response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele A.	25730470	1447679203
CHAT	rs12246528	G	donepezil	efficacy	yes	Presented as trend test of AA,AG, and GG in responder vs non responder. Donepezil 84 patients, galantamine 52 patients, rivastigmine 22 patients. No significant differences in genotype by drug type. Patients assessed after 1 week and 4 weeks of therapy to adjust dosage and evaluate adverse events. Response rate assessed at 26 weeks of treatment.	Allele G is not associated with response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele A.	25730470	1447679013
CHAT	rs11101187	C	donepezil	efficacy	yes	Presented as trend test of CC, CT, and TT in responder vs non responder. Donepezil 84 patients, galantamine 52 patients, rivastigmine 22 patients. No significant differences in genotype by drug type. Patients assessed after 1 week and 4 weeks of therapy to adjust dosage and evaluate adverse events. Response rate assessed at 26 weeks of treatment.	Allele C is not associated with response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele T.	25730470	1447679019
CHAT	rs3793797	C	donepezil	efficacy	yes	Presented as trend test of CC, CT, and TT in responder vs non responder. Donepezil 84 patients, galantamine 52 patients, rivastigmine 22 patients. No significant differences in genotype by drug type. Patients assessed after 1 week and 4 weeks of therapy to adjust dosage and evaluate adverse events. Response rate assessed at 26 weeks of treatment.	Allele C is not associated with response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele T.	25730470	1447679224
CHAT	rs3793798	A	donepezil	efficacy	yes	Presented as trend test of AA, AT, and TT in responder vs non responder. Donepezil 84 patients, galantamine 52 patients, rivastigmine 22 patients. No significant differences in genotype by drug type. Patients assessed after 1 week and 4 weeks of therapy to adjust dosage and evaluate adverse events. Response rate assessed at 26 weeks of treatment.	Allele A is not associated with response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele T.	25730470	1447679267
CHAT	rs3793800	A	donepezil	efficacy	yes	Presented as trend test of AA, AG, and GG in responder vs non responder. Donepezil 84 patients, galantamine 52 patients, rivastigmine 22 patients. No significant differences in genotype by drug type. Patients assessed after 1 week and 4 weeks of therapy to adjust dosage and evaluate adverse events. Response rate assessed at 26 weeks of treatment.	Allele A is not associated with response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele G.	25730470	1447679275
CHAT	rs3793801	C	donepezil	efficacy	yes	Presented as trend test of CC, CT, and TT in responder vs non responder. Donepezil 84 patients, galantamine 52 patients, rivastigmine 22 patients. No significant differences in genotype by drug type. Patients assessed after 1 week and 4 weeks of therapy to adjust dosage and evaluate adverse events. Response rate assessed at 26 weeks of treatment.	Allele C is not associated with response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele T.	25730470	1447679282
CHAT	rs3810950	G	donepezil	efficacy	yes	Presented as trend test of AA,AG, and GG in responder vs non responder. Donepezil 84 patients, galantamine 52 patients, rivastigmine 22 patients. No significant differences in genotype by drug type. Patients assessed after 1 week and 4 weeks of therapy to adjust dosage and evaluate adverse events. Response rate assessed at 26 weeks of treatment.	Allele G is not associated with response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele A.	25730470	1447678993
CHAT	rs4838391	C	donepezil	efficacy	yes	Presented as trend test of CC, CT, and TT in responder vs non responder. Donepezil 84 patients, galantamine 52 patients, rivastigmine 22 patients. No significant differences in genotype by drug type. Patients assessed after 1 week and 4 weeks of therapy to adjust dosage and evaluate adverse events. Response rate assessed at 26 weeks of treatment.	Allele C is not associated with response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele T.	25730470	1447678999
CHAT	rs4838392	G	donepezil	efficacy	yes	Presented as trend test of AA,AG, and GG in responder vs non responder. Donepezil 84 patients, galantamine 52 patients, rivastigmine 22 patients. No significant differences in genotype by drug type. Patients assessed after 1 week and 4 weeks of therapy to adjust dosage and evaluate adverse events. Response rate assessed at 26 weeks of treatment.	Allele G is not associated with response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele A.	25730470	1447679007
CHAT	rs12266458	C	donepezil	efficacy	yes	Presented as trend test of CC, CT, and TT in responder vs non responder. Donepezil 84 patients, galantamine 52 patients, rivastigmine 22 patients. No significant differences in genotype by drug type. Patients assessed after 1 week and 4 weeks of therapy to adjust dosage and evaluate adverse events. Response rate assessed at 26 weeks of treatment.	Allele C is not associated with response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele T.	25730470	1447679044
CHAT	rs1917818	G	donepezil	efficacy	yes	Presented as trend test of AA,AC, and CC (reverse strand) in responder vs non responder. Donepezil 84 patients, galantamine 52 patients, rivastigmine 22 patients. No significant differences in genotype by drug type. Patients assessed after 1 week and 4 weeks of therapy to adjust dosage and evaluate adverse events. Response rate assessed at 26 weeks of treatment.	Allele G is not associated with response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele T.	25730470	1447679196
CHAT	rs2177369	GG	rivastigmine	efficacy	no	Response to rivastimine was assessed by the mini mental state examination (MMSE) at baseline and at 1, 3, 9 and 15 months after beginning therapy.	Genotype GG is not associated with response to rivastigmine in people with Alzheimer Disease as compared to genotypes AA + AG.	18780301	1185235085
CHAT	rs2177370	A	donepezil	efficacy	yes	Presented as trend test of CC,TC, and TT (reverse strand) in responder vs non responder. Donepezil 84 patients, galantamine 52 patients, rivastigmine 22 patients. No significant differences in genotype by drug type. Patients assessed after 1 week and 4 weeks of therapy to adjust dosage and evaluate adverse events. Response rate assessed at 26 weeks of treatment.	Allele A is associated with increased response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele G.	25730470	1447678959
CHAT	rs3793790	G	donepezil	efficacy	yes	Presented as trend test of AA,AG, and GG in responder vs non responder. Donepezil 84 patients, galantamine 52 patients, rivastigmine 22 patients. No significant differences in genotype by drug type. Patients assessed after 1 week and 4 weeks of therapy to adjust dosage and evaluate adverse events. Response rate assessed at 26 weeks of treatment.	Allele G is associated with increased response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele A.	25730470	1447678987
CHAT	rs3793791	C	donepezil	efficacy	yes	Presented as trend test of CC, CT, and TT in responder vs non responder. Donepezil 84 patients, galantamine 52 patients, rivastigmine 22 patients. No significant differences in genotype by drug type. Patients assessed after 1 week and 4 weeks of therapy to adjust dosage and evaluate adverse events. Response rate assessed at 26 weeks of treatment.	Allele C is not associated with response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele T.	25730470	1447679025